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Abstract
Introduction: Patients with rheumatoid arthritis (RA) treated with abatacept (ABT) are at increased risk for
vaccine-preventable infections. The aim of the present study is to evaluate the humoral response to 23-valent
pneumococcal polysaccharide (PPSV23) vaccination in RA patients receiving ABT.
Methods: The immunogenicity study was nested within a randomized, double-blind placebo-controlled study,
designed to evaluate the efficacy of the PPSV23. PPSV23 was given to 111 RA patients, who were classified into
three groups: RA control (n = 35), methotrexate (MTX) alone (n = 55), and ABT (n = 21). Before and 4–6 weeks after
vaccination, we measured the patients’ concentrations of antibodies against pneumococcal serotypes 6B and 23F
using an enzyme-linked immunosorbent assay and determined their antibody functionality using a multiplexed
opsonophagocytic killing assay, reported as the opsonization index (OI).
Results: The pneumococcal serotype-specific IgG concentrations and OIs were both significantly increased in all
treatment groups in response to PPSV23 vaccination. In the ABT group, the IgG responses for the 6B serotype
were lower compared with those in the MTX alone or control groups, whereas the OI responses were similar to
those in the other two groups. In a subgroup analysis, the pneumococcal serotype-specific IgG responses were
significantly lower in both serotypes (6B and 23F) in the ABT/MTX group; however, the OI responses in the
ABT group were not different from the control group. There was no association between the pneumococcal
serotype-specific IgG and OI responses for the 6B serotype in patients receiving ABT in contrast to the control or
MTX alone patients. No severe adverse effects were observed in any of the treatment groups.
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Conclusions: OI responses indicate antibody functionality rather than simply their amount, so the similarity of
these measurements between all three groups suggests that RA patients receiving ABT still benefit from receiving
the PPSV23 vaccination, even though they produce less IgG in response to it. The results suggest an influence of
ABT on the humoral response to PPSV23 vaccination under MTX treatment; however, preserved opsonin
responses are expected in RA patients treated with ABT plus MTX.
Trial registration: University Hospital Medical Information Network Clinical Trials Registry: UMIN000009566.
Registered 12 December 2012.
Keywords: Abatacept, Methotrexate, Opsonization index, Rheumatoid arthritis, 23-valent pneumococcal polysaccharide
Introduction
Patients with autoimmune rheumatic diseases are more
susceptible to infectious complications during the course
of their diseases. Rheumatoid arthritis (RA) treatment
can induce immunosuppression and increase the risk of
infection [1]. The introduction of biologics has been a
major achievement in treating these diseases, but an in-
creased risk of infection associated with these therapies
has become evident [2]. Some infections can be prevented
by vaccination, which if used appropriately will decrease
the burden of infection [3]. It is important to determine if
RA patients receiving biologics have normal responses to
vaccines.
Abatacept (ABT) selectively modulates the CD80/
CD86:CD28 co-stimulatory signal required for full T-cell
activation [4]. The efficacy of ABT has previously been
demonstrated both in RA patients with an inadequate
response to methotrexate (MTX) and in RA patients with
an inadequate response to anti-tumor necrosis factor
(TNF) therapy [5], and ABT has been approved for the
treatment of RA in a number of countries, including Japan.
The impact of ABT on humoral responses to T-cell-
dependent antigens, such as bacteriophage X174 and
keyhole limpet hemocyanin, was previously evaluated in
patients treated with ABT, and the responses to these
antigens were reduced [6].
Polysaccharides are able to elicit immune responses in
the absence of T-cell help, although the magnitude of
the response can be marginally affected by immunosup-
pressive treatments [7]. Recent studies with pneumococcal
polysaccharide vaccines with a limited number of RA pa-
tients were performed, without control groups, suggesting
an adequate response [8]. Regarding the pneumococcal
vaccine, the polysaccharide and less T cell-dependent na-
ture of the antigen [9], may account for the preserved
immune response during costimulatory modulation with
ABT. The results from the earlier report would be
strengthened by an inclusion of the relevant control groups
because it is crucial to have a group of age-matched RA
patients under treatment with MTX alone for comparison
[10]. The objective of this study was to investigate the 23-
valent pneumococcal polysaccharide vaccine (PPSV23) in
patients with established RA who were being treated with
ABT alone or in combination with MTX.
Methods
Study design and patient population
This immunogenicity study was nested within a random-
ized, double-blind, controlled trial designed to evaluate the
effectiveness of the PPSV23 in reducing the incidence of
pneumonia as a primary endpoint. Patients with clinically
diagnosed RA were recruited in Japanese National Hospital
Organization (NHO) hospitals across Japan (n = 32) from
September 2010 to December 2012 [11]. A total of 932 RA
patients were enrolled and randomized 1:1 to receive either
the PPSV23 or placebo. Of these, paired serum samples were
obtained before and after vaccination from 703 patients, 353
of which received PPSV23. Among these 353 patients,121
patients receiving disease-modifying anti-rheumatic drugs
(DMARDs), MTX, or ABT with/without MTX were
subjected to the nested study for vaccine immunogenicity
(Fig. 1).
Eligible patients were also found to be at risk for de-
veloping respiratory infections. RA patients were divided
into the following groups: (1) patients with rheumatoid
lung disease, (2) patients with RA treated with biological
agents, and (3) patients treated with immunosuppressive
agents. Patients who had received PPSV23 previously
were excluded from this study. This study complies with
the principles of the Declaration of Helsinki and was ap-
proved by the appropriate institutional review boards at
each participating center. All patients provided written
informed consent. This study was approved by the ethical
committees of NHO central IRB (No. 0512014, 2012) for
all participating NHO hospitals and was registered with
UMIN-CTR (UMIN000009566).
Intervention
Patients were randomly assigned to receive either 0.5 ml
(25 μg) of PPSV23 (Pneumovax NP, Merck Sharp &
Dohme Corp., Tokyo, Japan) or 0.5 ml of a placebo (sodium
chloride) subcutaneously in the upper arm. The vaccines
were prepared in a masked fashion for those who adminis-
tered them, blinding both the administrator of the vaccine
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and the patient to the type of vaccine given. Vaccine and
placebo were presented in identical single dose syringes
and needle combinations that were labelled with sequential
study numbers only. A statistician who was not on the
study team carried out the randomization using a random
number table and numbered the containers accordingly.
Enzyme-linked immunosorbent assays for serotype-
specific IgG
Blood samples were drawn at vaccination and four to six
weeks thereafter, and stocked at −30 °C. Enzyme-linked
immunosorbent assays (ELISAs) for serotype-specific
IgG were performed to measure the concentration of
each type of antibody as previously described [12]. For
the measurement of IgG specificity for the 6B and 23F
serotypes, we specifically performed our ELISAs accord-
ing to the World Health Organization (WHO) standard
procedure that used the international reference serum,
89SF-3 (graciously supplied by Dr. Carl E. Frasch). To
improve the specificity of the assay, a pneumococcal cell
wall polysaccharide (C-PS) and pneumococcal 22F poly-
saccharide pre-absorption step was performed on the
samples. The reference serum was pre-absorbed with
only C-PS [13, 14]. Detailed protocols are available at
www.vaccine.uab.edu/ELISAProtocol(89SF).pdf.
Multiplexed opsonophagocytic assays
To measure antibody functionality against pneumococ-
cus, we performed multiplexed opsonophagocytic assays
(OPAs) for pneumococcal serotypes 6B and 23F, using
differentiated HL-60 cells and an antibiotic-resistant tar-
get bacteria strain, at the Research Institute for Micro-
bial Disease, Osaka University, as previously described
[15]. The quality control serum included in each assay
was prepared from pooled sera of adults immunized
with PPV23. Opsonization indices (OIs) were defined as
the serum dilution that led to 50 % death of target
bacteria. Opsotiter 3, an excel-based data processing
program, was used to convert colony counts to OIs,
according to the WHO protocol available at www.vaccine.
uab.edu/UAB-MOPA.pdf.
Antibody response
Fold increases relative to pre-vaccination values (post-
vaccination value to pre-vaccination value ratios) were de-
termined. Positive antibody response was defined as a two-
fold or more increase in IgG concentrations or as a ten-fold
or more increase in OIs as described previously [12].
Statistical analysis
The study population was classified into three groups
based on the RA treatment at the time of vaccination.
Clinical and demographic characteristics of each group
were expressed as mean ± standard deviation or as a per-
centage. Changes in IgG geometric mean concentrations
(GMCs) and OPA titers before and after the vaccination
were compared using the paired-sample t test. To compare
categorical variables in response rates between groups, the
Pearson chi-square test was used. Continuous variables
were compared using Mann–Whitney tests. For all tests,
probability values (p values) less than 0.05 were considered
statistically significant. All the statistical analyses were
performed using the Statistical Analysis System (SAS) and
SPSS version 18 software (SPSS, Chicago, IL, USA).
Results
Clinical and demographic characteristics
A total of 989 RA patients were assessed for eligibility,
and 929 patients were recruited and randomized. Of these,
121 patients receiving disease-modifying anti-rheumatic
drugs (DMARDs), MTX, or ABT with/without MTX were
subjected to the nested study for vaccine immunogenicity
(Fig. 1). The clinical and demographic characteristics of
these 121 subjected patients are summarized in Table 1.
The study population was classified into three groups:
DMARD treatment only (RA control group; n = 35), MTX
monotherapy (MTX alone group, n = 55), and ABT treat-
ment (n = 24, mean dose; 547 + 127.9 mg/4 weeks). The
mean ages of patients in the ABT group were significantly
lower compared to those in the control group. The three
groups were otherwise similar. All patients fulfilled the
criteria of safety required for vaccine injection, and no
serious side effects were observed after vaccination.
Pneumococcal serotype-specific IgG concentrations
To evaluate the effect of ABT treatment on the level of
pneumococcal serotype-specific IgG produced following
PPS23V vaccination in RA patients, enzyme-linked immuno-
sorbent assays were performed to measure the serotype
Fig. 1 Flow diagram of patient recruitment
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6B- and 23F-specific IgG levels in patients from each of
the three groups before and after vaccination. The ratios
between post- and pre-vaccination antibody concentra-
tions are summarized in Table 2. After vaccination with
PPSV23, the geometric mean concentrations (GMCs) of
both serotype 6B- and 23F-specific IgG were increased in
all groups. However, there were large differences in the
fold induction of GMC responses among the groups with
regard to treatments; for 6B serotypes, a higher post-
GMC was obtained in the control (2.38 times) and MTX
Table 1 Clinical and demographic characteristics of RA patients prior to pneumococcal vaccination
RA control MTX group ABT group p Values between
treatment groupsn = 35 n = 55 n = 21
Male/female 12/23 11/44 4/17 0.251
Age, mean ± SD (years) 70.5 ± 10.8 63.8 ± 11.5 59.8 ± 12.0 0.002
Weight, mean ± SD (Kg) 53.3 ± 9.5 52.9 ± 11.8 55.2 ± 10.1 0.501
BMI, mean ± SD 21.8 ± 3.5 21.7 ± 3.7 23.2 ± 4.9 0.344
RA duration, mean ± SD (years) 11.7 ± 12.5 14.1 ± 10.9 13.5 ± 11.2 0.144
MTX dose, mean ± SD (mg/week) - 7.8 ± 2.4 7.2 ± 3.4(15/21) -
ABT dose, mean ± SD (mg/4 week) - - 547.6 ± 127.9 -
Use of prednisolone, number of patients (%) 21 (60.0) 30 (54.5) 13(61.9) 0.798
Prednisolone dose, mean ± SD (mg/day) 6.06 ± 4.23 4.98 ± 2.97 5.04 ± 2.85 0.769
DAS28(CRP), mean ± SD 2.79 ± 1.17 2.61 ± 0.98 2.48 ± 1.31 0.565
SDAI, mean ± SD 9.03 ± 6.32 8.15 ± 7.33 8.32 ± 7.29 0.593
CDAI, mean ± SD 7.83 ± 5.40 7.46 ± 6.73 7.87 ± 6.54 0.721
IP (%) 6 (17.1) 7 (12.7) 3(14.3) 0.844
COPD (%) 3 (8.6) 1 (1.8) 2(9.5) 0.251
Smoking history (%) 10(28.6) 13(23.6) 6(28.6) 0.839
Data were obtained immediately before pneumococcal vaccination. p values between treatment groups were determined using the Kruskal-Wallis test. p values
were calculated with the chi-square test for qualitative data. RA rheumatoid arthritis, MTX methotrexate, ABT abatacept, BMI body mass index, DAS28 Disease Activity
Score 28, SDAI simplified disease activity index, CDAI clinical disease activity index, IP interstitial pneumonia, COPD chronic obstructive pulmonary disease
Table 2 Concentrations of pneumococcal polysaccharide antigen serotype-specific IgG antibodies and opsonization indices in the
RA treatment groups before and after 23-valent pneumococcal polysaccharide vaccination
RA Control MTX group ABT group
n = 35 n = 55 n = 21
IgG GMCs (μg/ml)
6B Before 0.84(0.58 to 1.11) 1.42(0.86 to 1.97) 1.12(0.80 to 1.45)
After 4.05(2.13 to 5.97)* 4.36(2.17 to 6.55)* 2.29(0.76 to 3.83)
Fold increase 2.38(1.41 to 5.62) 1.75(1.15 to 3.11) 1.41(0.87 to 3.09)
23F Before 1.17(0.85 to 1.48) 1.79(1.33 to 2.25) 1.22(0.79 to 1.65)
After 11.61(4.16 to 19.07)* 7.41(4.48 to 10.33)* 4.61(2.95 to 6.27)*
Fold increase 3.36(1.85 to 9.42) 2.00(1.27 to 5.48) 2.45(1.23 to 7.44)
GM-OIs
6B Before 17.24(10.96 to 23.53) 150.79(14.85 to 286.74) 61.55(13.78 to 109.32)
After 981.15(407.24 to 1555.05)* 584.29(270.29 to 898.28)* 1345.19(383.97 to 2306.41)*
Fold increase 10.22(1.92 to 79.48) 2.57(1.22 to 22.40) 14.83(2.93 to 163.03)
23F Before 63.21(−6.79 to 133.20) 52.11(14.04 to 90.18) 138.40(−87.83 to 364.63)
After 713.49(307.97 to 1119.01)* 724.56(336.93 to 1112.19)* 887.76(172.11 to 1603.42)*
Fold increase 6.86(2.50 to 27.14) 3.75(1.47 to 38.32) 2.97(1.37 to 76.09)
IgG GMCs and GM-OIs are expressed as the mean (95 % CI). Fold increases are expressed as the median (IQR). Differences between pre- and post-vaccination
GMCs of serotype-specific IgG were assessed using a paired-sample t test
RA rheumatoid arthritis, MTX methotrexate, ABT abatacept, GMC geometric mean concentration, GM-OI geometric mean opsonization index, IQR interquartile range
*p < 0.05 compared with pre-vaccination IgG GMCs or GM-OIs
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alone (1.75 times) groups compared with that in the ABT
(1.23 times, no significant increase) group.
Opsonophagocytic killing assays
To determine the antibody functionality in these groups,
we performed multiplexed opsonophagocytic killing as-
says and reported the results as the opsonization index
(OI). The post-vaccination OIs increased significantly in
all treatment groups. The ratios between pre- and post-
vaccination are provided in Table 2. In contrast to the
GMC (6B) results, there were no differences in the fold
induction of OIs for either serotype (6B or 23F) among
the ABT and control or MTX alone groups. In this assay,
the ABT group showed an antibody response rate that
was equivalent to those in the control and MTX groups.
Antibody response rates
The GMC response rates, given as the percentage of pa-
tients with a positive antibody response, for patients in
the ABT group were significantly decreased compared
with those for patients in the control or MTX alone
groups for serotype 6B (Fig. 2a). For OIs specific to sero-
type 6B and 23F, the ABT group showed an equivalent
antibody response rate, similarly defined as the percent-
age of patients with a positive OI response, compared
with the control or MTX groups (Fig. 2b).
Subgroup analysis for patients receiving ABT/MTX
combination treatment
Notably, ABT is primarily used in combination with MTX,
and ABT monotherapy is limited in Japan. Therefore, we
Fig. 2 a Comparison of post-vaccination GMC responses in patients receiving DMARDs (control), MTX and ABT. Percentages of patients with an
increase in 6B or 23F serotype-specific IgG concentration greater than two-fold are shown. There was a significant difference in the 6B serotype-
specific IgG response rates between control and ABT groups (p = 0.034). Data were compared using the Pearson chi-square test. b Comparison of
post-vaccination OIs responses in patients receiving DMARDs (control), MTX and ABT. Percentage of patients with an increase in OIs for serotypes
6B or 23F greater than ten-fold are shown. There was no significant difference in the response rates among control, MTX and ABT groups. GMC
geometric mean concentration, DMARDS disease modifying anti-rheumatic drugs, MTX methotrexate, ABT abatacept, OIs opsonization index
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compared the patients receiving both ABT and MTX
(ABT/MTX) to control patients (receiving DMARDs alone
or MTX alone). It appears that ABT/MTX groups had an
insignificant increase in the GMC for the 6B serotype and
an even lower increase in the GMC for the 23F serotype
after PPSV23 vaccination compared with control groups
(Table 3). However, the post-vaccination OI responses for
both serotypes in the patients receiving ABT/MTX com-
bination therapy were equivalent to those in the control
group patients. Similarly, a lower proportion of RA patients
receiving ABT/MTX had a geometric mean concentration
(GMC) increase greater than two-fold for both serotypes;
however, the rates of patients with OIs greater than ten-fold
for both serotypes were not different between the ABT/
MTX and control groups (Fig. 3). Because the opsono-
phagocytic activity (OPA) is a measurement of antibody
function, these results suggest that while the GMC re-
sponse rate is lower in patients receiving ABT/MTX
combination therapy, the antibodies that are produced
in response to PPSV23 vaccination by this group are
similarly functional.
Associations between pneumococcal serotype-specific
IgG and OI responses
We assessed the associations between the pneumococcal
serotype-specific IgG and OI responses for serotype 6B,
in which lower 6B-specific IgG responses were demon-
strated in the ABT group. In the control or MTX groups,
the functional OI responses were almost exclusively
observed in patients who had an optimum pneumococcal
serotype-specific IgG response (Fig. 4a). In contrast, in the
MTX/ABT group, a positive OI response was also ob-
served in patients who lacked an optimum pneumococcal
serotype-specific IgG response (Fig. 4a). The OIs in pa-
tients with negative IgG responses were higher in the
MTX/ABT group than those in the control or MTX
groups (Fig. 4b). Therefore, an association between the
pneumococcal serotype-specific IgG response and the
OI response was not demonstrated in patients receiving
MTX/ABT combination therapy.
Safety
There were no reported adverse events associated with
PPSV23 vaccination in the patients from this study.
Discussion
This study was nested within a randomized, double-
blind, controlled trial designed to evaluate the effective-
ness of the PPSV23, and immunogenicity of PPSV23
vaccination in patients receiving ABT was investigated.
ABT, a CTLA-4-immunoglobulin-fusion protein, inhibits
T cell activation by binding to CD80 and CD86, thus
blocking the interaction with CD28 [4]. ABT acts by
inhibiting the costimulatory pathway, which is essential
for the generation of an immune response to protein
and peptide antigens [16]. The requirement of T-cell co-
stimulation for B-cell affinity maturation and for the
production of high affinity IgG antibodies has potential
Table 3 Concentrations of pneumococcal polysaccharide antigen serotype-specific IgG antibodies and opsonization indices in the
RA treatment groups before and after 23-valent pneumococcal polysaccharide vaccination
RA Control MTX group ABT/MTX group
n = 35 n = 55 n = 15
IgG GMCs (μg/ml)
6B Before 0.84(0.58 to 1.11) 1.42(0.86 to 1.97) 1.19(0.73 to 1.65)
After 4.05(2.13 to 5.97)* 4.36(2.17 to 6.55)* 2.49(0.29 to 4.70)
Fold increase 2.38(1.41 to 5.62) 1.75(1.15 to 3.11) 1.19(0.77 to 2.44)
23F Before 1.17(0.85 to 1.48) 1.79(1.33 to 2.25) 1.17(0.63 to 1.71)
After 11.61(4.16 to 19.07)* 7.41(4.48 to 10.33)* 3.78(1.87 to 5.70)*
Fold increase 3.36(1.85 to 9.42) 2.00(1.27 to 5.48) 1.96(1.15 to 5.99)
GM-OIs
6B Before 17.24(10.96 to 23.53) 150.79(14.85 to 286.74) 43.33(0.15 to 86.51)
After 981.15(407.24 to 1555.05)* 584.29(270.29 to 898.28)* 1454.80(109.29 to 2800.31)*
Fold increase 10.22(1.92 to 79.48) 2.57(1.22 to 22.40) 14.65(2.96 to 193.79)
23F Before 63.21(−6.79 to 133.20) 52.11(14.04 to 90.18) 178.13(−130.27 to 486.54)
After 713.49(307.97 to 1119.01)* 724.56(336.93 to 1112.19)* 880.73(−81.54 to 1843.01)*
Fold increase 6.86(2.50 to 27.14) 3.75(1.47 to 38.32) 2.50(1.33 to 35.74)
IgG GMCs and GM-OIs are expressed as the mean (95 % CI). Fold increases are expressed as the median (IQR). Differences between pre- and post-vaccination GMCs
of serotype-specific IgG were assessed using a paired-sample t test
RA rheumatoid arthritis, MTX methotrexate, ABT abatacept, GMC geometric mean concentration, GM-OI geometric mean opsonization index, CI, confidence interval,
IQR interquartile index
*p < 0.05 compared with pre-vaccination IgG GMCs or GM-OIs
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implications for pneumococcal vaccination [17]. In an
open-label, controlled study in healthy subjects, tetanus
toxoid vaccine and PPSV23 were each used to assess the
impact of ABT on the memory response to a T-cell-
dependent protein antigen and to a less T-cell-dependent
polysaccharide antigen, respectively [18]. While ABT blunted
the immune response (geometric mean titers) to both
vaccinations, it did not significantly inhibit the ability
of healthy subjects to develop a two-fold response to ei-
ther vaccine [18]. The reduced antibody response to
the T-cell dependent protein tetanus toxoid antigen is
consistent with the known ABT modulation of memory
T-cell activation, whereas the inhibition of B–T cell help is
likely responsible for the reduced antibody response to T
cell-independent polysaccharide antigens, such as the
pneumococcal vaccine [19]. Kapetanovic et al. studied the
effect of ABT on the antibody response to PPSV23 in pa-
tients with RA (compared with TCZ) and reported mar-
ginally diminished antibody responses in the ABT group
[8]. Thus, although there is a paucity of data, it appears
that ABT is able to blunt the effectiveness of the immune
response, but does not significantly inhibit the ability of
healthy subjects and patients with RA to develop a clinic-
ally significant positive immune response to PPSV23.
RA patients frequently use ABT in combination with
traditional DMARDs, including MTX [20]. However, MTX
was shown to be associated with reduced immune re-
sponses to PPSV23 [10]. It is, therefore, crucial to evaluate
Fig. 3 a Comparison of post-vaccination GMC responses in patients receiving DMARDs (control), MTX and ABT/MTX. Percentages of patients with
an increase in 6B and 23F serotype-specific IgG concentration greater than two-fold are shown. There were significant differences in the 6B and
6B/23F serotype-specific IgG response rates between control and ABT/MTX groups (6B; p = 0.012, 6B + 23F; p = 0.021). Data were compared using
the Pearson chi-square test. b Comparison of post-vaccination OI responses in patients receiving DMARDs (control), MTX and ABT/MTX. Percentage of
patients with an increase in OIs for serotypes 6B and 23F greater than ten-fold are shown. There was no significant difference in the response rates
among control, MTX and ABT/MTX groups. Data were compared using the Pearson chi-square test. GMC geometric mean concentration,
DMARDS disease modifying anti-rheumatic drugs, MTX methotrexate, ABT abatacept, OIs opsonization index
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the immunogenicity of PPSV23 by comparing RA patients
treated with ABT with those treated with MTX. Block-
age of the CD80/CD86 co-stimulatory molecules by a
variety of activated immune cells can regulate the im-
mune responses [21]. This may result in T cell activa-
tion and diminished B-cell immunological response as
the consequence of inadequate differentiations into
plasma cells.
In the present study, the magnitude of the IgG response
to PPSV23 was decreased in RA patients treated with
ABT. However, the decreased IgG responses to PPSV23
did not affect the OI responses in these patients. This may
have resulted from a diminished B cell immune response
as a consequence of inadequate stimulation, such as a lack
of the T cell help needed for B cell differentiation. How-
ever, we also demonstrated that ABT, even with MTX, did
not affect the OI responses to PPSV23 vaccination in RA
patients. The mechanism by which ABT with or without
MTX affects the IgG responses, but not the OI responses
against PPSV23, has not been examined in this study.
Unlike ELISA results, OPA results are ideal surrogate
markers for vaccine efficacy as they mimic the host defense
responses [9]. Recent evidence has shown that older adults
have a lower capacity to opsonize pneumococci despite
normal IgG levels, owing to a lack of anti-pneumococcal
IgM antibodies [22]. These poor correlations between
opsonic activity and IgG levels have also been shown in
patients who are in immunosuppressive states [23]. RA
patients receiving ABT/MTX showed a similar dissoci-
ation between opsonic activity and levels of IgG against
the polysaccharide capsule of pneumococci.
Pneumococcal polysaccharides are T cell-independent
antigens. ABT/MTX treatment may partly impair the T
cell-independent antibody response that is normally trig-
gered by PPSV23 vaccination because B cells also express
CD80 and CD86 [24], and ABT may have some effects on
Fig. 4 a Relationship between IgG and OI responses after PPSV23 vaccination. The 6B serotype-specific IgG (X axis) and OIs (Y axis) responses
were plotted in the comparison of three groups (control, MTX, ABT). Positive OI responses were demonstrated in patients receiving ABT with
negative IgG responses. b Comparisons of means of OIs between patients with negative or positive serotype 6B-specific IgG responses among
three treatment groups (control, MTX, ABT). Error bars represent SD of mean OIs. There was no significant difference in mean OIs between patients
with or without positive serotype-6B-specific IgG response in ABT group. IgG immunoglobulin G, OIs opsonization indices, MTX methotrexate,
ABT abatacept, SD standard deviation
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B cell activation in the presence of MTX, as described
previously [21]. In contrast, ABT/MTX treatment did
not inhibit PPSV23 vaccination-induced OPA. The rela-
tive activities of IgG and IgM antibodies may contribute
to the preserved OPA in RA patients treated with ABT/
MTX as described previously [25]. Strong correlations
between ELISA results and OPA results have been ob-
served in many studies [26]; however, no such correlation
was found in RA patients receiving ABT. In this setting,
OPA has become a useful measure of pneumococcal
vaccine immunogenicity. The introduction of pneumococ-
cal conjugate vaccines may expand the options available
for protecting RA patients against pneumococcal infec-
tions. Abatacept-treated RA patients had decreased anti-
body response against pneumococcal conjugate vaccines 7
(PCV7) compared to controls and tocilizumab-treated RA
patients [8]. Abatacept attenuates activation of T cells by
blocking the interaction between CD80/86 and CD28, a
co-stimulation signal for T cell activation, which may
contribute to the impaired antibody responses after PCV7
vaccination. Whereas another immunogenicity studies
comparing PPSV23 and PCV7 revealed that the OPA
and geometric antibody titers PCV7 were comparable to
those of PPSV23in RA patients [27]. Further immunogen-
icity studies comparing PPSV23 and PCV13 are needed.
The primary limitation of this study is the relatively
small number of RA patients in each group, particularly
the group for ABT/MTX combination treatment. Other
limitations include the fact that the antibody response is
only a surrogate marker of vaccine-induced protection
and the inclusion of a number of patients who were treated
with ABT in combination with remedies other than MTX.
Furthermore, we choose to investigate serotypes 6B and
23F because they are the main causative serotypes of
penicillin-resistant pneumococcal pneumonia in Japan
[28]. Lastly, the antibody concentrations necessary for
protection against invasive pneumococcal disease in
adults have not been clearly defined [29]. Strengths of
the present study are the standardized blood sampling
and the way that the analyses were blinded for demo-
graphic and treatment data.
Conclusions
In conclusion, our results suggest that the T cell co-
stimulation modulator, ABT, with or without MTX, has an
influence on the humoral responses to PPSV23 vaccin-
ation; however, even in patients concomitantly treated with
MTX, the opsonization responses against PPSV23 were
preserved in RA patients treated with ABT. These data
suggest immunization with PPSV23 resulted in a preserved
immune response in RA patients treated with ABT.
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